| Literature DB >> 27115490 |
Pilar Bueno-Vargas1,2, Manuel Manzano1, Javier Diaz-Castro2, Inmaculada López-Aliaga2, Ricardo Rueda1, Jose María López-Pedrosa1.
Abstract
Nutrition during pregnancy and <span class="Disease">lactation could exert a key role not only on maternal bone, but also could influence the skeletal development of the offspring. This study was performed in <span class="Species">rats to assess the relationship between maternal dietary intake of prebiotic oligofructose-enriched inulin and its role in bone turnover during gestation and lactation, as well as its effect on offspring peak bone mass/architecture during early adulthood. Rat dams were fed either with standard rodent diet (CC group), calcium-fortified diet (Ca group), or prebiotic oligofructose-enriched inulin supplemented diet (Pre group), during the second half of gestation and lactation. Bone mineral density (BMD) and content (BMC), as well as micro-structure of dams and offspring at different stages were analysed. Dams in the Pre group had significantly higher trabecular thickness (Tb.Th), trabecular bone volume fraction (BV/TV) and smaller specific bone surface (BS/BV) of the tibia in comparison with CC dams. The Pre group offspring during early adulthood had an increase of the lumbar vertebra BMD when compared with offspring of CC and Ca groups. The Pre group offspring also showed significant increase versus CC in cancellous and cortical structural parameters of the lumbar vertebra 4 such as Tb.Th, cortical BMD and decreased BS/BV. The results indicate that oligofructose-enriched inulin supplementation can be considered as a plausible nutritional option for protecting against maternal bone loss during gestation and lactation preventing bone fragility and for optimizing peak bone mass and architecture of the offspring in order to increase bone strength.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27115490 PMCID: PMC4846003 DOI: 10.1371/journal.pone.0154120
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Experimental design.
CC, Control group; Ca, Calcium-fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group. Sacrifices were carried out at the end of each period, delivery, pups; weaning, pups and dams; adolescence, pups. *Prebiotic oligofructose-enriched inulin source provided by Orafti is a 1/1 mixture of oligofructose and high performance inulin.
Composition of the experimental diets used in the study.
| AIN93-G (CC group) | AIN93-G+Ca (Ca group) | AIN93-G+Pre (Pre group) | |
|---|---|---|---|
| 71.8 | 71.8 | 71.8 | |
| Soy oil | 71.8 | 71.8 | 71.8 |
| 183.1 | 183.1 | 183.1 | |
| 661.6 | 661.6 | 661.6 | |
| Cellulose | 49.5 | 49.5 | 0.0 |
| Prebiotic Oligofructose-enriched inulin | 0.0 | 0.0 | 75.0 |
| Calcium (g) | 5.25 | 10.5 | 5.25 |
| Magnesium (mg) | 539.0 | 539.0 | 539.0 |
| Manganesium (mg) | 15.0 | 15.0 | 15.0 |
| Phosphorous (g) | 3.15 | 3.15 | 3.15 |
| Zinc (mg) | 39.9 | 39.9 | 39.9 |
| Vitamin A (IU) | 4200 | 4200 | 4200 |
| Vitamin D3 (IU) | 1200 | 1200 | 1200 |
| Vitamin E (IU) | 90 | 90 | 90 |
| Vitamin K1 (mg) | 1.08 | 1.08 | 1.08 |
| 3880.0 | 3880.0 | 3840.0 |
CC, Control group; Ca, Calcium-fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group.
*Prebiotic oligofructose-enriched inulin source provided by Orafti is a 1/1 mixture of oligofructose and high performance inulin.
Fig 2Maternal body weight evolution.
Mean values with their standard deviations. (—)CC Group, Control group; (---) Ca Group, Calcium-fortified group; (···) Pre Group, Prebiotic oligofructose-enriched inulin supplemented group. GD, Gestational day; LD, Lactation day.
Fig 3Pups body weight gain.
Mean values with their standard deviations. (—)CC Group, Control group; (---) Ca Group, Calcium-fortified group; (···) Pre Group, Prebiotic oligofructose-enriched inulin supplemented group. Significant differences (p<0.05) * CC group vs Ca group; # Ca group vs Pre group.
pDEXA analysis of bone mineral content (BMC) and density (BMD), from dams at sacrifice (end of lactation).
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 10) | (n = 10) | (n = 10) | |
| BMC (g) | 0.3075 ± 0.0114 | 0.2813 ± 0.0128 | 0.3127 ± 0.0146 |
| BMD (g/cm2) | 0.1532 ± 0.0038 | 0.1419 ± 0.0044 | 0.1585 ± 0.0057 |
| BMC (g) | 0.2394 ± 0.0062 | 0.2122 ± 0.0094 | 0.2407 ± 0.0096 |
| BMD (g/cm2) | 0.1229 ± 0.0019 | 0.1161 ± 0.0019 | 0.1258 ± 0.0032 |
| BMC (g) | 0.3064 ± 0.0106 | 0.2815 ± 0.0180 | 0.3138 ± 0.0165 |
| BMD (g/cm2) | 0.1473 ± 0.0029 | 0.1373 ± 0.0048 | 0.1500 ± 0.0039 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium-fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group. Statistical significance was defined as p<0.05.
CC significantly different vs the CC group
Ca significantly different vs the Ca group.
Trabecular architecture of dams bones at sacrifice (end of lactation).
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| BV/TV | 0.1584 ± 0.0116 | 0.1291 ± 0.0086 | 0.1521 ± 0.0154 |
| BS/BV (1/mm) | 34.29 ± 1.27 | 33.77 ± 0.62 | 32.59 ± 1.45 |
| Tb. Th (mm) | 0.0736 ± 0.0023 | 0.0715 ± 0.0018 | 0.0744 ± 0.0020 |
| Tb. Sp (mm) | 0.6185 ± 0.0482 | 0.7150 ± 0.050 | 0.6169 ± 0.0767 |
| Tb. N (1/mm) | 1.816 ± 0.1389 | 1.535 ± 0.0985 | 1.516 ± 0.077 |
| Conn.D | 70.01 ± 3.14 | 57.85 ± 4.25 | 73.97 ± 11.47 |
| BV/TV | 0.1274 ± 0.0094 | 0.1211 ± 0.0065 | 0.1723 ± 0.0213 |
| BS/BV (1/mm) | 43.55 ± 1.13 | 41.30 ± 0.85 | 38.33 ± 1.31 |
| Tb. Th (mm) | 0.0614 ± 0.0014 | 0.0631 ± 0.0011 | 0.0669 ±0.0017 |
| Tb. Sp (mm) | 0.4036 ± 0.0300 | 0.4956 ± 0.0364 | 0.3795 ± 0.0472 |
| Tb. N (1/mm) | 2.598 ± 0.1933 | 2.151 ± 0.1371 | 2.979 ± 0.3915 |
| Conn.D | 73.78 ± 4.57 | 66.18 ± 4.71 | 100.1 ± 14.58 |
| BV/TV | 0.2759 ± 0.0127 | 0.2580 ± 0.0143 | 0.2985 ± 0.0234 |
| BS/BV (1/mm) | 30.27 ± 1.01 | 31.83 ± 1.11 | 28.92 ± 1.18 |
| Tb. Th (mm) | 0.0750 ± 0.0018 | 0.0713 ± 0.0016 | 0.0768 ± 0.0019 |
| Tb. Sp (mm) | 0.2544 ± 0.0063 | 0.2571 ± 0.0095 | 0.2419 ± 0.0119 |
| Tb. N (1/mm) | 3.978 ± 0.081 | 3.947 ± 0.124 | 4.140 ± 0.179 |
| Conn.D | 104.0 ± 4.1 | 104.6 ± 3.6 | 99.1 ± 4.5 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; BV/TV, Bone volume/total volume ratio; BS/BV, Bone surface/bone volume; Tb.Th, Trabecular Thickness; Tb.Sp, Trabecular Separation; Tb.N, Trabecular Number; Conn.D, Connectivity Density, LV4, lumbar vertebra 4. Statistical significance was defined as p < 0.05
CC significantly different vs the CC group
Casignificantly different vs the Ca group.
Fig 4Representative micro CT images of trabecular bone in the tibia of dams.
CC, Control group; Ca, Calcium-fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group.
Bone biomarkers in serum and 12h-urine from the dams at sacrifice (end of lactation).
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 10) | (n = 10) | (n = 10) | |
| Osteocalcin (mg/mol creatinine) | 7489 ± 759.4 | 11133 ± 1008 | 9763 ± 869.6 |
| Alkaline phosphatase (U/mmol creatinine) | 3874 ± 726.3 | 5045 ± 639.8 | 3242 ± 380.3 |
| PTH (mg/mol creatinine) | 1030 ± 113.0 | 880.5 ± 120.3 | 828.0 ± 90.74 |
| DPD (μmol/mol creatinine) | 166.3± 13.03 | 219.4 ± 26.59 | 187.5 ± 20.22 |
| PYD (μmol/mol creatinine) | 214.4 ± 11.46 | 242.4 ± 26.30 | 213.1 ±19.87 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; Osteocalcin, Alkaline phosphatase and PTH (Parathyroid hormone) were measure in serum. DPD (Deoxypyridinoline) and PYD (Pyridinoline) were measured in 12h-acidified urine. Statistical significance was defined as p < 0.05.
CC significantly different vs the CC group.
Trabecular architecture of offspring bones at delivery period.
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| Length (mm) | 4.283 ± 0.076 | 3.971 ± 0.058 | 4.099 ± 0.069 |
| BV/TV | 0.476 ± 0.030 | 0.468 ± 0.012 | 0.445 ± 0.033 |
| BS/BV (1/mm) | 19.47 ± 1.09 | 23.90 ± 1.23 | 22.41 ± 1.151 |
| Tb. Th (mm) | 0.105 ± 0.006 | 0.079 ± 0.003 | 0.091 ± 0.005 |
| Tb. Sp (mm) | 0.117 ± 0.009 | 0.091 ± 0.004 | 0.118 ± 0.012 |
| Tb. N (1/mm) | 4.53 ± 0.13 | 5.89 ± 0.15 | 4.87 ± 0.22 |
| Length (mm) | 0.739 ± 0.016 | 0.756 ± 0.020 | 0.693 ± 0.023 |
| BV/TV | 0.742 ± 0.029 | 0.671 ± 0.038 | 0.676 ± 0.034 |
| BS/BV (1/mm) | 17.39 ± 1.55 | 18.81 ± 0.71 | 21.12 ± 1.38 |
| Tb. Th (mm) | 0.122 ± 0.012 | 0.093 ± 0.003 | 0.098 ± 0.006 |
| Tb. Sp (mm) | 0.041 ± 0.005 | 0.040 ± 0.004 | 0.047 ± 0.005 |
| Tb. N (1/mm) | 6.35 ± 0.46 | 7.20 ± 0.37 | 6.97 ± 0.27 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; BV/TV, Bone volume/total volume ratio; BS/BV, Bone surface/bone volume; Tb.Th, Trabecular Thickness; Tb.Sp, Trabecular Separation; Tb.N, Trabecular Number; LV4, lumbar vertebra 4. Statistical significance was defined as p < 0.05.
CC significantly different vs the CC group
Casignificantly different vs the Ca group.
Trabecular architecture of offspring bones at weaning period.
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| Length (mm) | 19.44 ± 0.09 | 18.45 ± 0.28 | 18.81 ± 0.24 |
| BV/TV | 0.717 ± 0.033 | 0.657 ± 0.043 | 0.704 ± 0.008 |
| BS/BV (1/mm) | 6.548 ± 0.506 | 7.812 ± 0.929 | 7.467 ± 0.239 |
| Tb. Th (mm) | 0.312 ± 0.023 | 0.295 ± 0.020 | 0.269 ± 0.009 |
| Tb. Sp (mm) | 0.122 ± 0.012 | 0.154 ± 0.021 | 0.126 ± 0.011 |
| Tb. N (1/mm) | 2.318 ± 0.098 | 2.235 ± 0.071 | 2.539 ± 0.064 |
| Length (mm) | 3.260 ± 0.098 | 2.737 ± 0.118 | 3.191 ± 0.048 |
| BV/TV | 0.714 ± 0.038 | 0.764 ± 0.035 | 0.747 ± 0.038 |
| BS/BV (1/mm) | 8.068 ± 1.053 | 5.778 ± 0.267 | 8.418 ± 0.584 |
| Tb. Th (mm) | 0.227 ± 0.042 | 0.252 ± 0.030 | 0.242 ± 0.016 |
| Tb. Sp (mm) | 0.112 ± 0.013 | 0.073 ± 0.006 | 0.081 ± 0.011 |
| Tb. N (1/mm) | 3.051 ± 0.288 | 3.150 ± 0.246 | 3.027 ± 0.052 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; BV/TV, Bone volume/total volume ratio; BS/BV, Bone surface/bone volume; Tb.Th, Trabecular Thickness; Tb.Sp, Trabecular Separation; Tb.N, Trabecular Number; LV4, lumbar vertebra 4. Statistical significance was defined as p < 0.05
CC significantly different vs the CC group
Casignificantly different vs the Ca group.
pDEXA analysis of the femur bone mineral content (BMC) and density (BMD) from offspring at adolescence.
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| BMC (g) | 0.3643 ± 0.0090 | 0.3557 ± 0.0095 | 0.3580 ± 0.0164 |
| BMD (g/cm2) | 0.1782 ± 0.0033 | 0.1741 ± 0.0036 | 0.1787 ± 0.0042 |
| BMC (g) | 0.2770 ± 0.0079 | 0.2752 ± 0.0080 | 0.2697 ± 0.0106 |
| BMD (g/cm2) | 0.1376 ± 0.0026 | 0.1353 ± 0.0025 | 0.1368 ± 0.0027 |
| BMC (g) | 0.3228 ± 0.0093 | 0.2982 ± 0.0144 | 0.3457 ± 0.0175 |
| BMD (g/cm2) | 0.1807 ± 0.0047 | 0.1670 ± 0.0043 | 0.1974 ± 0.0069 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; Statistical significance was defined as p < 0.05
CC significantly different vs the CC group
Casignificantly different vs the Ca group.
Trabecular and cortical architecture lumbar vertebra 4 from offspring at adolescence.
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| BV/TV | 0.306 ± 0.007 | 0.373 ± 0.021 | 0.340 ± 0.017 |
| BS/BV (1/mm) | 28.370 ± 0.460 | 23.640 ± 0.723 | 25.440 ± 1.160 |
| Tb. Th (mm) | 0.071 ±0.001 | 0.082 ± 0.004 | 0.080 ± 0.003 |
| Tb. Sp (mm) | 0.161 ± 0.005 | 0.139 ± 0.007 | 0.156 ± 0.007 |
| Tb. N (1/mm) | 4.331 ± 0.103 | 4.524 ± 0.095 | 4.257 ± 0.115 |
| C.BMD (mgHA/cm3) | 385.40 ± 12.07 | 450.90 ± 14.95 | 435.20 ± 18.31 |
| pMOI(mm4) | 6.619 ± 0.352 | 7.026 ± 0.494 | 6.892 ± 0.355 |
| C.Th (mm) | 0.1674 ± 0.0045 | 0.1773 ± 0.0051 | 0.1836 ± 0.0058 |
| C.Sp (%) | 0.2743 ± 0.0086 | 0.2391 ± 0.0071 | 0.2578 ± 0.0106 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; BV/TV, bone volume/total volume ratio; Tb.Th, Trabecular Thickness; Tb.Sp, Trabecular Separation; Tb.N, Trabecular Number; C.BMD Cortical Bone Mineral Density, pMOI, polar Moment of Inertia, C.Th, Cortical Thickness, C.Sp, Cortical Porosity. Statistical significance was defined as p < 0.05
CC significantly different vs the CC group.
Fig 5Representative micro CT images of trabecular bone in the LV4 of offspring at adolescence.
CC, Control group; Ca, Calcium-fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group.
Bone biomarkers in serum and 12h-acidified urine from offspring at adolescence.
| CC group | Ca group | Pre group | |
|---|---|---|---|
| (n = 8) | (n = 8) | (n = 8) | |
| Osteocalcin (mg/mol creatinine) | 8404 ± 398 | 9698 ± 593 | 9323 ± 815 |
| Alkaline phosphatase (U/mmol creatinine) | 1475 ± 139 | 1962 ± 136 | 1311 ± 139 |
| DPD (μmol/mol creatinine) | 198.8 ± 16.5 | 210.2 ± 28.7 | 242.0 ± 19.8 |
| PTH (μg/mol creatinine) | 1313 ± 200 | 1019 ± 131 | 1107 ± 109 |
Values are expressed as mean ± S.E.M. CC, Control group; Ca, Calcium fortified group; Pre, Prebiotic oligofructose-enriched inulin supplemented group; Osteocalcin, Alkaline phosphatase and PTH (Parathyroid hormone) were measure in serum. DPD (Deoxypyridinoline) was measured in 12h-acidified urine. Statistical significance was defined as p < 0.05.
CC significantly different vs the CC group
Casignificantly different vs the Ca group.